Journey Biosciences, a biotechnology company offering biomarker-based predictive risk screening technologies for diabetes-related complications, has announced the launch of its flagship product NaviDKD.
NaviDKD is a blood test that proactively assesses the risk of kidney disease in people with diabetes years before clinical signs or symptoms appear. Along with its proprietary Compass reporting platform, NaviDKD also provides actionable insights for preventing and managing kidney complications before they occur.
Adam Graybill, Chief Executive Officer of Journey Biosciences, said, "For the one-in-three people with diabetes who will develop diabetic kidney disease, NaviDKD provides an opportunity to fundamentally change their ultimate health outcomes. By identifying those at elevated or high risk of developing DKD before any symptoms or clinical indications, the conversation between doctor and patient can focus on taking proactive, preventative action instead of reacting to an unwanted diagnosis."
Journey Biosciences received CLIA certification for its lab in August 2022 and all NaviDKD blood samples are processed in this Cleveland, Ohio-based lab.
Click here to read the original news article.